Current management strategies for intraocular retinoblastoma Journal Article


Authors: Kim, J. W.; Abramson, D. H.; Dunkel, I. J.
Article Title: Current management strategies for intraocular retinoblastoma
Abstract: Survival rates for retinoblastoma patients have increased dramatically over the last century, with documented 5-year survival figures reaching 87-99% in developed countries. During the last decade, there has been a dramatic paradigm shift in the treatment approach for intraocular retinoblastoma, emphasising chemoreduction protocols and minimising the use of external beam radiation. The recognition of the increased risk for second non-ocular cancers with external beam radiation contributed to the growing emergence of chemotherapy. Although chemoreduction protocols vary slightly between institutions, many centres are currently treating intraocular retinoblastoma with carboplatin, vincristine and etoposide as a three-drug regimen given in two to six cycles. Clinical studies have demonstrated that systemic chemotherapy must be combined with other modalities, such as laser treatment and cryotherapy, for adequate tumour control and many eyes with advanced intraocular disease require salvage therapy with radiation or enucleation. Therefore, modern centres treating retinoblastoma continue to manage patients with a variety of modalities, individualising the therapy according to the patient's presentation and clinical course. © 2007 Adis Data Information BV. All rights reserved.
Keywords: cancer chemotherapy; cancer survival; fatigue; review; salvage therapy; cancer risk; antineoplastic agents; cancer radiotherapy; radiation dose; combined modality therapy; cancer staging; animals; carboplatin; anemia; etoposide; leukopenia; nausea; thrombocytopenia; vomiting; radiotherapy; vincristine; clinical protocol; retinoblastoma; retinal neoplasms; survival time; immunotherapy; cancer size; acute myeloblastic leukemia; brachytherapy; surgery; enucleation; external beam radiotherapy; eye enucleation; cancer classification; children; hydroxyapatite; cyclosporin; teniposide; cryotherapy; low level laser therapy; silicone; etoposide, therapeutic use; epipodophyllotoxin; carboplatin, therapeutic use; retinoblastoma, treatment; vincristine, therapeutic use; orbit implant
Journal Title: Drugs
Volume: 67
Issue: 15
ISSN: 0012-6667
Publisher: Adis International Ltd  
Date Published: 2007-01-01
Start Page: 2173
End Page: 2185
Language: English
PUBMED: 17927283
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 4" - "Export Date: 17 November 2011" - "CODEN: DRUGA" - "Source: Scopus"
Citation Impact
MSK Authors
  1. Ira J Dunkel
    371 Dunkel
  2. Jonathan Wano Kim
    6 Kim
  3. David H Abramson
    390 Abramson
Related MSK Work